Denisa Negru

Dr. Denisa Negru


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 December 2022 in Cells
Verified
Journal Article
Open access
PDF file
DNDenisa Negru
Denisa Negru
PNPaul Negru
Paul Negru
Simona BungăuSimona Bungău
Simona Bungău
TBTapan Behl
Tapan Behl
Syed Shams ul HassanSyed Shams ul Hassan
Syed Shams ul Hassan
Delia Mirela TitDelia Mirela Tit
Delia Mirela Tit
Alzheimer’s disease (AD), once considered a rare disease, is now the most common form of dementia in the elderly population. Current drugs (cholinesterase inhibitors and glutamate antagonists) are safe but of limited benefit to most patients, offering symptomatic relief without successful cure of the disease. Since the last several decades, there has been a great need for the development of a treatment that might cure the underlying causes of AD and thereby slow its progression in vulnerable individuals. That is why phase I, II, and III studies that act on several fronts, such as cognitive improvement, symptom reduction, and enhancing the basic biology of AD, are imperative to stop the disease. This review discusses current treatment strategies, summarizing the clinical features and pharmacological properties, along with molecular docking analyses of the existing medications.

18 July 2022 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
PNPaul Andrei Negru
Paul Andrei Negru
DNDenisa Negru
Denisa Negru
TBTapan Behl
Tapan Behl
ABAlexa Florina Bungau
Alexa Florina Bungau
RMRuxandra-Cristina Marin
Ruxandra-Cristina Marin
Simona BungăuSimona Bungău
Simona Bungău
Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is considered the etiological agent of the disease that caused the COVID-19 pandemic, and for which there is currently no effective treatment. This pandemic has shown that the rapid identification of therapeutic compounds is critical (when a new virus with high transmissibility occurs) to prevent or reduce as much as possible the loss of human lives. To meet the urgent need for drugs, many strategies were applied for the discovery, respectively the identification of potential therapies / drugs for SARS-CoV-2. Molecular docking and virtual screening are two of the in silico tools/techniques that provided the identification of few SARS-CoV-2 inhibitors, removing ineffective or less effective drugs and thus preventing the loss of resources such as time and additional costs. The main target of this review is to provide a comprehensive overview of how in-silico tools have been used in the crisis management of anti-SARS-CoV-2 drugs, especially in virtual screening of substances used in the treatment of SARS-CoV-2 infection and analysis of compounds with known action on structurally similar proteins from other viruses; also, completions were added to the way in which these methods came to meet the requirements of biomedical research in the field. Moreover, the importance and impact of the topic approached for researchers was highlighted by conducting an extensive bibliometric analysis.